Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Osteoarthritis and Cartilage

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.joca.2016.09.006PMID 27638130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

  2016cited by this paper
• Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor

  2015cited by this paper
• The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life

  2015cited by this paper
• Plasma and synovial fluid autotaxin correlate with severity in knee osteoarthritis.

  2015cited by this paper
• Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.

  2014cited by this paper
• Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis

  2012cited by this paper
• A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials

  2012cited by this paper
• LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning

  2012cited by this paper
• Insights into autotaxin: how to produce and present a lipid mediator

  2011cited by this paper
• Antinociceptive effect of cyclic phosphatidic acid and its derivative on animal models of acute and chronic pain

  2011cited by this paper
• Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site.

  2011cited by this paper
• Lipids: LPA activates TRPV1--and it hurts.

  2011cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

  2010cited by this paper
• NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System

  2010cited by this paper
• Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation

  2010cited by this paper
• A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation

  2010cited by this paper
• Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Healing

  2010cited by this paper
• Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain

  2009cited by this paper
• Effective relief of neuropathic pain by adeno-associated virus-mediated expression of a small hairpin RNA against GTP cyclohydrolase 1

  2009cited by this paper
• Regulation of Lysophosphatidic Acid Receptor Expression and Function in Human Synoviocytes: Implications for Rheumatoid Arthritis?

  2008cited by this paper
• Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.

  2008cited by this paper
• Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling

  2008cited by this paper
• Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain

  2008cited by this paper
• Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.

  2008cited by this paper
• Regulation and biological activities of the autotaxin-LPA axis.

  2007cited by this paper
• Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: Increased expression of ATF‐3 and pharmacological characterisation

  2007cited by this paper
• Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia.

  2006cited by this paper
• Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development

  2006cited by this paper
• Development and pharmacological characterization of a rat model of osteoarthritis pain

  2005cited by this paper
• Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling

  2004cited by this paper
• Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis.

  2003cited by this paper
• Animal models of osteoarthritis.

  2001cited by this paper
• Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip

  2001cited by this paper
• Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: NSAID: AN UPDATE ON THEIR ANALGESIC EFFECTS

  1995cited by this paper
• NSAID: an update on their analgesic effects.

  1995cited by this paper
• Enzymatic determination of phospholipase D activity with choline oxidase.

  1978cited by this paper

• Virtual screening and molecular dynamics investigations using natural compounds against autotaxin for the treatment of chronic pain

  2024cites this paper
• Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein–Ligand Interactions and High Selectivity

  2024cites this paper
• Unfolding the Mystery Behind the Onset of Chondrocyte Hypertrophy during Chondrogenesis: Toward Designing Advanced Permanent Cartilage‐mimetic Biomaterials

  2023cites this paper
• Joint Damage and Neuropathic Pain in Rats Treated With Lysophosphatidic Acid

  2022cites this paper
• Immunohistochemical evaluation of autotaxin and lubricin in mild osteoarthritic rat model performing moderate physical activity.

  2022cites this paper
• Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain

  2022cites this paper
• Identifying Novel ATX Inhibitors via Combinatory Virtual Screening Using Crystallography-Derived Pharmacophore Modelling, Docking Study, and QSAR Analysis

  2020cites this paper
• Histopathological Signatures of the Femoral Head in Patients with Osteonecrosis and Potential Applications in a Multi-Targeted Approach: A Pilot Study

  2020cites this paper
• Effect of autotaxin inhibition in a surgically-induced mouse model of osteoarthritis

  2020cites this paper
• Hematopoietic PBX-interacting protein mediates cartilage degeneration during the pathogenesis of osteoarthritis

  2019cites this paper
• Oxidized Lipids in Persistent Pain States

  2019cites this paper
• Autotaxin and chronic inflammatory diseases.

  2019cites this paper
• Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases

  2019cites this paper
• Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation

  2018cites this paper
• The Metabolome and Osteoarthritis: Possible Contributions to Symptoms and Pathology

  2018cites this paper
• Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib

  2017cites this paper
• Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.

  2016cites this paper